Cargando…

Systemic Brain Delivery of Antisense Oligonucleotides across the Blood–Brain Barrier with a Glucose‐Coated Polymeric Nanocarrier

Current antisense oligonucleotide (ASO) therapies for the treatment of central nervous system (CNS) disorders are performed through invasive administration, thereby placing a major burden on patients. To alleviate this burden, we herein report systemic ASO delivery to the brain by crossing the blood...

Descripción completa

Detalles Bibliográficos
Autores principales:	Min, Hyun Su, Kim, Hyun Jin, Naito, Mitsuru, Ogura, Satomi, Toh, Kazuko, Hayashi, Kotaro, Kim, Beob Soo, Fukushima, Shigeto, Anraku, Yasutaka, Miyata, Kanjiro, Kataoka, Kazunori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317551/ https://www.ncbi.nlm.nih.gov/pubmed/31995252 http://dx.doi.org/10.1002/anie.201914751

Ejemplares similares

Fine-Tuning of Hydrophobicity in Amphiphilic Polyaspartamide Derivatives for Rapid and Transient Expression of Messenger RNA Directed Toward Genome Engineering in Brain
por: Kim, Hyun Jin, et al.
Publicado: (2019)

Effect of Mixing Ratio of Oppositely Charged Block Copolymers on Polyion Complex Micelles for In Vivo Application
por: Nakamura, Noriko, et al.
Publicado: (2020)

Glycaemic control boosts glucosylated nanocarrier crossing the BBB into the brain
por: Anraku, Y., et al.
Publicado: (2017)

Effects of combinations of gapmer antisense oligonucleotides on the target reduction
por: Yanagidaira, Mitsugu, et al.
Publicado: (2023)

Tunable nonenzymatic degradability of N-substituted polyaspartamide main chain by amine protonation and alkyl spacer length in side chains for enhanced messenger RNA transfection efficiency
por: Naito, Mitsuru, et al.
Publicado: (2019)

Gold nanocarriers for transport of oligonucleotides across brain endothelial cells
por: Fatima, Nayab, et al.
Publicado: (2020)

A single-cell map of antisense oligonucleotide activity in the brain
por: Mortberg, Meredith A, et al.
Publicado: (2023)

A single-cell map of antisense oligonucleotide activity in the brain
por: Mortberg, Meredith A, et al.
Publicado: (2023)

In vivo rendezvous of small nucleic acid drugs with charge-matched block catiomers to target cancers
por: Watanabe, Sumiyo, et al.
Publicado: (2019)

Drug Discovery Perspectives of Antisense Oligonucleotides
por: Kim, Yeonjoon
Publicado: (2023)

Lipid nanoparticles for antisense oligonucleotide gene interference into brain border-associated macrophages
por: Calero, Macarena, et al.
Publicado: (2022)

Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndrome
por: Lee, Dongwon, et al.
Publicado: (2023)

Nanocarriers for Delivery of Oligonucleotides to the CNS
por: Male, David, et al.
Publicado: (2022)

Increased Enzyme Loading in PICsomes via Controlling Membrane Permeability Improves Enzyme Prodrug Cancer Therapy Outcome
por: Goto, Akinori, et al.
Publicado: (2023)

Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)

Molecular Mechanisms of Antisense Oligonucleotides
por: Crooke, Stanley T.
Publicado: (2017)

Antisense oligonucleotides: A primer
por: Scoles, Daniel R., et al.
Publicado: (2019)

Antisense Oligonucleotides and RNA Interference
por: Kher, Gitanjali, et al.
Publicado: (2011)

Hypergravity Increases Blood–Brain Barrier Permeability to Fluorescent Dextran and Antisense Oligonucleotide in Mice
por: Dubayle, David, et al.
Publicado: (2023)

Antisense Oligonucleotide-Mediated Transcript Knockdown in Zebrafish
por: Pauli, Andrea, et al.
Publicado: (2015)

Evaluation of off‐target effects of gapmer antisense oligonucleotides using human cells
por: Yoshida, Tokuyuki, et al.
Publicado: (2019)

Identification of nucleobase chemical modifications that reduce the hepatotoxicity of gapmer antisense oligonucleotides
por: Yoshida, Tokuyuki, et al.
Publicado: (2022)

Radiation enhances the delivery of antisense oligonucleotides and improves chemo-radiation efficacy in brain tumor xenografts
por: Ambady, Prakash, et al.
Publicado: (2021)

Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1
por: Ait Benichou, Siham, et al.
Publicado: (2022)

Opportunities and challenges for antisense oligonucleotide therapies
por: Kuijper, Elsa C., et al.
Publicado: (2020)

Silencing Antibiotic Resistance with Antisense Oligonucleotides
por: Jani, Saumya, et al.
Publicado: (2021)

In-silico study of antisense oligonucleotide antibiotics
por: Chen, Erica S., et al.
Publicado: (2023)

Exon-skipping antisense oligonucleotides for cystic fibrosis therapy
por: Kim, Young Jin, et al.
Publicado: (2022)

Multi-Armed Star-Shaped Block Copolymers of Poly(ethylene glycol)-Poly(furfuryl glycidol) as Long Circulating Nanocarriers
por: Nakagawa, Yasuhiro, et al.
Publicado: (2023)

Manipulation of PK-M mutually exclusive alternative splicing by antisense oligonucleotides
por: Wang, Zhenxun, et al.
Publicado: (2012)

Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension
por: Yasuhara, Hidenori, et al.
Publicado: (2022)

A New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy
por: Kim, Kyuho, et al.
Publicado: (2022)

Delivering Antisense Oligonucleotides across the Blood‐Brain Barrier by Tumor Cell‐Derived Small Apoptotic Bodies
por: Wang, Yulian, et al.
Publicado: (2021)

Lipid nanoparticle delivery limits antisense oligonucleotide activity and cellular distribution in the brain after intracerebroventricular injection
por: Byrnes, Amy E., et al.
Publicado: (2023)

Antisense Oligonucleotide Therapeutics for Cystic Fibrosis: Recent Developments and Perspectives
por: Kim, Young Jin, et al.
Publicado: (2023)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

Improved targeting of miRNA with antisense oligonucleotides
por: Davis, Scott, et al.
Publicado: (2006)

Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol
por: Nishina, Tomoko, et al.
Publicado: (2015)

Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides
por: Goyenvalle, Aurelie, et al.
Publicado: (2016)

Splice-switching antisense oligonucleotides as therapeutic drugs
por: Havens, Mallory A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ol9f7ig848gfqrnj8ufr1f5htn